financetom
Business
financetom
/
Business
/
CyberArk Software Swings to Q1 Net Income as Revenue Rises; Q2 Guidance Issued, 2024 Outlook Lifted
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CyberArk Software Swings to Q1 Net Income as Revenue Rises; Q2 Guidance Issued, 2024 Outlook Lifted
May 2, 2024 6:59 AM

09:41 AM EDT, 05/02/2024 (MT Newswires) -- CyberArk Software ( CYBR ) reported Q1 non-GAAP net income Thursday of $0.75 per diluted share, swinging from a loss of $0.17 a year earlier.

Analysts polled by Capital IQ expected $0.28.

Revenue for the quarter ended March 31 was $221.6 million, up from $161.7 million a year earlier.

Analysts surveyed by Capital IQ expected $213.3 million.

For Q2, the company said it expects non-GAAP net income of $0.34 to $0.44 per diluted share on revenue of $215 million to $221 million. Analysts polled by Capital IQ expect adjusted EPS of $0.30 on revenue of $221.2 million.

For 2024, the company said it now expects non-GAAP net income of $1.88 to $2.07 per diluted share, up from its prior guidance of $1.63 to $1.81. Analysts surveyed by Capital IQ expect $1.76.

Revenue for the year is now expected between $928 million and $938 million, up from its previous outlook of $920 million to $930 million. Analysts polled by Capital IQ expect $927.2 million.

Price: 229.70, Change: -7.46, Percent Change: -3.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Street Color: Turkish Airlines Orders Four Additional Boeing 777 Freighters
--Street Color: Turkish Airlines Orders Four Additional Boeing 777 Freighters
Jul 2, 2024
09:18 AM EDT, 07/02/2024 (MT Newswires) -- Price: 185.71, Change: -0.99, Percent Change: -0.53 ...
Legend Biotech Says Myeloma Drug Shows Positive Overall Survival Results
Legend Biotech Says Myeloma Drug Shows Positive Overall Survival Results
Jul 2, 2024
09:20 AM EDT, 07/02/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said Tuesday that a late-stage study of its drug Carvykti showed positive overall survival results over other treatments in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three previous treatments. The company said the study evaluated the safety and efficacy of Carvykti compared with...
Aecon Utilities Buying Electrical Distribution Utility Contractor Xtreme Powerline for US$73 Million
Aecon Utilities Buying Electrical Distribution Utility Contractor Xtreme Powerline for US$73 Million
Jul 2, 2024
09:18 AM EDT, 07/02/2024 (MT Newswires) -- Aecon Group ( AEGXF ) said Tuesday that its subsidiary Aecon Utilities Group agreed to acquire a majority stake in Xtreme Powerline Construction, a Michigan-based electrical distribution utility contractor, for a base purchase price of about US$73 million. The transaction is being financed through Aecon Utilities' standalone committed revolving credit facility. Xtreme specializes...
Tesla Produces 410,831 Vehicles, Delivers 443,956 in Q2
Tesla Produces 410,831 Vehicles, Delivers 443,956 in Q2
Jul 2, 2024
09:18 AM EDT, 07/02/2024 (MT Newswires) -- Tesla (TSLA) produced 410,831 vehicles and delivered 443,956 in Q2, the company said Tuesday. Tesla produced 386,576 Model 3/Y vehicles during the quarter and delivered 422,405. The company produced and delivered 24,255 and 21,551, respectively, of all other models in Q2. The company said it deployed 9.4 GWh of energy storage products, its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved